Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

作者：Linong Ji, Leili Gao, Haibo Xue, Junhang Tian, Kun Wang, Hongwei� Jiang, Chun‐Jui Huang, Qiufang Lian, Mingxia Yuan, Ge Gao, Yibing Lu, Jie Han, Wenyan Fu, Haifang Wang, Yawei Zhang, Xiaoguang Shi, Binhong Wen, Bimin Shi, Wen Hu, Tonglan Guo, Ying Xing, Ya Li, Qingju Li, Qing Zheng, Ming Yang, Jing Ning, Mengying Guo, Yao Li, Hongbo Pan · 发表于：The Lancet Diabetes & Endocrinology · 年份：2025 · DOI：10.1016/s2213-8587(25)00141-x · 被引用次数：26 · 研究领域：Diabetes Treatment and Management、Pharmacology and Obesity Treatment、Bariatric Surgery and Outcomes